New drugs for ibuprofen dermatitis are recognized as breakthrough therapies

Source: Abbott vie, a biopharmaceutical company on January 8, 2018, announced today that the U.S FDA has given upadacitinib, a new drug under development, a breakthrough treatment for atopic dermatitis, to adult patients with moderate to severe atopic dermatitis who are suitable for systemic treatment This finding is based on the positive results of ABB vie's phase 2B clinical trial published in September 2017 The FDA's "breakthrough therapy identification" program aims to accelerate the development and review of drugs or therapies in development that have preliminary clinical evidence supporting their potential to significantly improve one or more clinically important endpoints Atopic dermatitis, also known as eczema, is a chronic inflammatory skin disease, which is characterized by skin ulcer, tissue exudation and scab, skin redness, severe itching and dry skin Symptoms may also include a rash or thickening and hardening of the skin In the United States, atopic dermatitis affects about 28 million people and may seriously affect the physical and mental health of patients Upadacitinib is an oral small molecule drug developed by abbvie, which can selectively inhibit Jak1 Jak1 plays an important role in the pathophysiological process of immune-mediated diseases Abbvie is conducting phase 2 and phase 3 clinical trials of upadacitinib for atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's disease Upadacitinib has not been approved by the regulatory authorities and its safety and effectiveness have not been determined ▲ molecular structure formula of upadacitinib (photo source: medchem express) Dr Michael Severino, chief scientific officer and executive vice president of research and Development Department of abbvie company, said: "our research and development history, scientific expertise and leading position in the field of immunity enable us to focus on the development of new therapies for emergent and unmet diseases At present, the treatment options for patients with atopic dermatitis are limited It is very important for us to address the needs of these patients We look forward to promoting uPA acitinib to the third stage of the study of atopic dermatitis " We look forward to more innovative therapies to alleviate the problems of dermatitis patients